Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NYXH Nyxoah	$7.47 -2.7%	$7.08	$5.55 ▼ $11.87	$254.43M	1.65	75,504 shs	23,747 shs
OBIO Orchestra BioMed	$2.78 -6.7%	$2.92	$2.37 ▼ $8.87	$106.50M	0.64	184,014 shs	3.18 million shs
PROF Profound Medical	$6.00 -2.4%	$5.40	$3.90 ▼ $11.42	$180.30M	0.48	65,124 shs	47,712 shs
TTOO T2 Biosystems	$0.14 -5.5%	$0.14	$0.06 ▼ $6.00	$2.98M	0.48	581,557 shs	17,303 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NYXH Nyxoah	0.00%	-3.11%	-4.84%	+7.02%	+7.17%
OBIO Orchestra BioMed	0.00%	-7.64%	-2.46%	-35.05%	-65.89%
PROF Profound Medical	0.00%	-5.51%	+14.72%	+3.09%	-28.49%
TTOO T2 Biosystems	0.00%	-2.07%	-5.53%	+15.20%	-97.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NYXH Nyxoah	3.2019 of 5 stars	3.5	5.0	1.6	0.0	0.6
OBIO Orchestra BioMed	3.0235 of 5 stars	3.6	5.0	2.4	1.7	0.0
PROF Profound Medical	2.3343 of 5 stars	3.5	2.0	1.3	2.5	0.6
TTOO T2 Biosystems	2.3347 of 5 stars	3.0	5.0	0.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NYXH Nyxoah	3.00	Buy	$14.50	94.11% Upside
OBIO Orchestra BioMed	3.20	Buy	$14.20	410.79% Upside
PROF Profound Medical	3.00	Buy	$11.50	91.67% Upside
TTOO T2 Biosystems	2.00	Hold	$5.00	3,428.58% Upside

Current Analyst Ratings Breakdown

Latest NYXH, OBIO, TTOO, and PROF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/9/2025	PROF Profound Medical	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Moderate Buy
5/5/2025	OBIO Orchestra BioMed	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
4/23/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/23/2025	PROF Profound Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $11.00
4/22/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/21/2025	NYXH Nyxoah	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/8/2025	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/4/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
4/3/2025	OBIO Orchestra BioMed	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/1/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NYXH Nyxoah	$4.89M	52.03	N/A	N/A	$3.60 per share	2.08
OBIO Orchestra BioMed	$2.64M	40.34	N/A	N/A	$0.87 per share	3.20
PROF Profound Medical	$10.68M	16.88	N/A	N/A	$2.01 per share	2.99
TTOO T2 Biosystems	$7.68M	0.39	N/A	N/A	($6.91) per share	-0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NYXH Nyxoah	-$64.10M	-$2.13	N/A	N/A	N/A	-1,571.39%	-63.37%	-46.67%	8/5/2025 (Estimated)
OBIO Orchestra BioMed	-$61.02M	-$1.78	N/A	N/A	N/A	-2,297.85%	-189.26%	-93.76%	N/A
PROF Profound Medical	-$27.82M	-$1.22	N/A	N/A	N/A	-269.35%	-70.41%	-57.22%	8/6/2025 (Estimated)
TTOO T2 Biosystems	-$50.08M	N/A	0.00	∞	N/A	-563.16%	N/A	-174.06%	7/28/2025 (Estimated)

Latest NYXH, OBIO, TTOO, and PROF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	NYXH Nyxoah	-$0.49	-$0.63	-$0.14	-$0.63	$1.64 million	$1.12 million
5/12/2025	Q1 2025	OBIO Orchestra BioMed	-$0.46	-$0.49	-$0.03	-$0.49	$0.39 million	$0.87 million
5/8/2025	Q1 2025	PROF Profound Medical	-$0.29	-$0.36	-$0.07	-$0.36	$4.78 million	$2.62 million
3/31/2025	Q4 2024	OBIO Orchestra BioMed	-$0.43	-$0.43	N/A	-$0.43	$0.79 million	$0.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NYXH Nyxoah	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A
PROF Profound Medical	N/A	N/A	N/A	N/A	N/A
TTOO T2 Biosystems	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NYXH Nyxoah	0.22	3.59	3.35
OBIO Orchestra BioMed	0.85	3.35	3.34
PROF Profound Medical	0.09	11.31	10.03
TTOO T2 Biosystems	N/A	0.40	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NYXH Nyxoah	N/A
OBIO Orchestra BioMed	53.55%
PROF Profound Medical	47.86%
TTOO T2 Biosystems	23.18%

Insider Ownership

Company	Insider Ownership
NYXH Nyxoah	N/A
OBIO Orchestra BioMed	8.10%
PROF Profound Medical	1.52%
TTOO T2 Biosystems	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NYXH Nyxoah	110	34.06 million	N/A	Not Optionable
OBIO Orchestra BioMed	4	38.31 million	35.21 million	Not Optionable
PROF Profound Medical	150	30.05 million	29.60 million	Optionable
TTOO T2 Biosystems	180	21.04 million	21.04 million	Optionable

NYXH, OBIO, TTOO, and PROF Headlines

Recent News About These Companies

TTOO T2 Biosystems, Inc. - Seeking Alpha

June 25, 2025 | seekingalpha.com

T2 Biosystems Inc. (TTOO) After Hours Quote

June 10, 2025 | nasdaq.com

Despite Promising Technology, Did Operational Cost Structure Take Down T2 Biosystems?

March 5, 2025 | 360dx.com3

T2 Biosystems initiates major layoffs, seeks asset sale

February 22, 2025 | uk.investing.com

Medical diagnostics firm T2 Biosystems cuts ‘substantially all’ workers

February 18, 2025 | bizjournals.com

T2 Biosystems to be delisted from Nasdaq

February 11, 2025 | msn.com

T2 Biosystems stock plunges to 52-week low of $0.22

January 30, 2025 | msn.com

T2 Biosystems Inc’s Stock Drama: Could This Be a Game-Changer for TTOO Investors?

January 24, 2025 | bovnews.comB

T2 Biosystems stock plunges to 52-week low of $0.25

January 21, 2025 | msn.com

T2 Biosystems amends loan terms, extends maturity date

January 18, 2025 | msn.com

T2 Biosystems reports preliminary Q4 revenue $2.3M

January 7, 2025 | markets.businessinsider.com

T2 Biosystems Reports Preliminary Financial Results For Q4 And Full Year 2024

January 7, 2025 | markets.businessinsider.com

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

January 7, 2025 | finance.yahoo.com

T2 Biosystems Enhances Governance and Leadership Stability

January 3, 2025 | tipranks.com

T2 Biosystems announces sale of four T2Dx Intruments to European distributor

December 18, 2024 | markets.businessinsider.com

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

December 18, 2024 | finance.yahoo.com

T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped

December 17, 2024 | markets.businessinsider.com

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

December 17, 2024 | markets.businessinsider.com

T2 Biosystems extends multi-year supplier agreement with Vizient

December 16, 2024 | markets.businessinsider.com

T2 Biosystems Extends Supplier Agreement with Vizient Through March 2026 for Rapid Sepsis Detection Products

December 16, 2024 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer
By Jeffrey Neal Johnson | June 19, 2025
View Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer

NYXH, OBIO, TTOO, and PROF Company Descriptions

Nyxoah NASDAQ:NYXH

$7.47 -0.21 (-2.73%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.67 +0.20 (+2.68%)

As of 04:00 AM Eastern

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Orchestra BioMed NASDAQ:OBIO

$2.78 -0.20 (-6.71%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.81 +0.03 (+1.08%)

As of 04:00 AM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Profound Medical NASDAQ:PROF

$6.00 -0.15 (-2.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.09 +0.09 (+1.50%)

As of 05:13 AM Eastern

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

T2 Biosystems NASDAQ:TTOO

$0.14 -0.01 (-5.47%)

As of 06/27/2025 03:57 PM Eastern

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time